Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016

Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016
Published Jul 20, 2016
98 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016, provides an overview of the Neisseria gonorrhoeae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neisseria gonorrhoeae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neisseria gonorrhoeae Infections and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neisseria gonorrhoeae Infections
- The report reviews pipeline therapeutics for Neisseria gonorrhoeae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Neisseria gonorrhoeae Infections therapeutics and enlists all their major and minor projects
- The report assesses Neisseria gonorrhoeae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Neisseria gonorrhoeae Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Neisseria gonorrhoeae Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline

  
Source:
Document ID
GMDHC8293IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Neisseria gonorrhoeae Infections Overview81
Therapeutics Development92
  Pipeline Products for Neisseria gonorrhoeae Infections Overview91
  Pipeline Products for Neisseria gonorrhoeae Infections Comparative Analysis101
Neisseria gonorrhoeae Infections Therapeutics under Development by Companies111
Neisseria gonorrhoeae Infections Therapeutics under Investigation by Universities/Institutes121
Neisseria gonorrhoeae Infections Pipeline Products Glance133
  Late Stage Products131
  Clinical Stage Products141
  Early Stage Products151
Neisseria gonorrhoeae Infections Products under Development by Companies161
Neisseria gonorrhoeae Infections Products under Investigation by Universities/Institutes171
Neisseria gonorrhoeae Infections Companies Involved in Therapeutics Development1812
  Allergan Plc181
  BioDiem Ltd191
  Biolytics Pharma201
  Debiopharm International SA211
  F. Hoffmann-La Roche Ltd.221
  GlaxoSmithKline Plc231
  Merck &Co., Inc.241
  Paratek Pharmaceuticals, Inc.251
  Recce Pty Ltd261
  Redx Pharma Plc271
  Sarepta Therapeutics, Inc.281
  Sumitomo Dainippon Pharma Co., Ltd.291
Neisseria gonorrhoeae Infections Therapeutics Assessment309
  Assessment by Monotherapy Products301
  Assessment by Target312
  Assessment by Mechanism of Action332
  Assessment by Route of Administration352
  Assessment by Molecule Type372
Drug Profiles3947
  Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections Drug Profile391
  BDM-I Drug Profile402
  Biologic for Neisseria Gonorrhoeae Infection Drug Profile421
  dalbavancin Drug Profile4310
  Debio-1453 Drug Profile531
  edodekin alfa SR Drug Profile541
  gepotidacin mesylate Drug Profile552
  Neisseria gonorrhoeae (virus like particle) vaccine Drug Profile571
  Neisseria gonorrhoeae vaccine Drug Profile581
  omadacycline tosylate Drug Profile596
  Recombinant Protein for Neisseria gonorrhoeae Infections Drug Profile651
  SM-295291 Drug Profile661
  SM-369926 Drug Profile671
  Small Molecule to Target Bacterial Cell Wall for Gonorrhoea and Tuberculosis Drug Profile681
  Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile691
  Small Molecules to Inhibit DNA Gyrase for Neisseria Gonorrhoeae Infections Drug Profile701
  Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections Drug Profile711
  Small Molecules to Inhibit Tubulin for Oncology and Neisseria Gonorrhoeae Infections Drug Profile721
  solithromycin Drug Profile7312
  VT-12008911 Drug Profile851
Neisseria gonorrhoeae Infections Dormant Projects861
Neisseria gonorrhoeae Infections Discontinued Products871
Neisseria gonorrhoeae Infections Product Development Milestones889
  Featured News &Press Releases881
    Dec 22, 2015: Cempra Enters Into a CRADA With the NIAID and Expands the Phase 3 Solithromycin Clinical Trial in Urogenital Gonorrhea to Include Additional Female Patients and Adolescents881
    Sep 10, 2015: Cempra to Present Data From Antibiotic Drug Solithromycin at ICAAC/ICC 2015 Meeting882
    Nov 19, 2014: Cempra to Receive BARDA Funding for 1b and Start-Up of Phase 2/3 Solithromycin Pediatric Studies901
    Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)902
    Aug 12, 2014: Cempra Initiates Phase 3 Clinical Trial in Patients With Uncomplicated Gonorrhea Infection921
    Apr 26, 2013: Cempra To Present Data On Solithromycin's Potential Against Urogenital Infections And Multidrug-Resistant Pathogens At ECCMID922
    Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I941
    Mar 31, 2012: Cempra's Solithromycin Demonstrates In Vitro Activity Against Antibiotic-Resistant Neisseria Gonorrhoeae Isolates943
Appendix972
  Methodology971
  Coverage971
  Secondary Research971
  Primary Research971
  Expert Panel Validation971
  Contact Us971
  Disclaimer981

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neisseria-gonorrhoeae-Infections-Pipeline-Review-H2-2016-2088-16256>
  
APA:
Global Markets Direct - Market Research. (2016). Neisseria gonorrhoeae Infections - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Neisseria-gonorrhoeae-Infections-Pipeline-Review-H2-2016-2088-16256>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.